Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paricalcitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 13/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.57 |
| ▸ | PGR | P06401 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paricalcitol SCHEMBL12915640 | 1.00 | VDR (0.68) | VDRHDAC6HDAC3HDAC2NR1I2 | |
| Paricalcitol SCHEMBL14491013 | 1.00 | VDR (0.68) | VDRHDAC6HDAC3HDAC2NR1I2 | |
| Paricalcitol SCHEMBL12464943 | 1.00 | VDR (0.68) | VDRHDAC6HDAC3HDAC2NR1I2 | |
| Paricalcitol SCHEMBL12397908 | 1.00 | VDR (0.68) | VDRHDAC6HDAC3HDAC2NR1I2 | |
| Paricalcitol SCHEMBL25447329 | 1.00 | VDR (0.68) | VDRHDAC6HDAC3HDAC2NR1I2 | |
| Paricalcitol SCHEMBL21836180 | 1.00 | VDR (0.68) | VDRHDAC6HDAC3HDAC2NR1I2 | |
| Paricalcitol SCHEMBL24066861 | 1.00 | VDR (0.68) | VDRHDAC6HDAC3HDAC2NR1I2 | |
| Paricalcitol SCHEMBL6945983 | 1.00 | VDR (0.68) | VDRHDAC6HDAC3HDAC2NR1I2 | |
| Paricalcitol SCHEMBL17354891 | 1.00 | VDR (0.68) | VDRHDAC6HDAC3HDAC2NR1I2 | |
| Paricalcitol SCHEMBL12553223 | 1.00 | VDR (0.68) | VDRHDAC6HDAC3HDAC2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026855-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PRE-CANCEROUS SKIN LESIONS | WASHINGTON UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| EP-3939593-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PRE-CANCEROUS SKIN LESIONS | Washington University (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210128732-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PRE-CANCEROUS SKIN LESIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-05-06 | — | — | US | disclosed |
| US-10905763-B2 | Compositions and methods for treatment of pre-cancerous skin lesions | WASHINGTON UNIVERSITY | 2021-02-02 | — | — | US | disclosed |
| US-20170246299-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PRE-CANCEROUS SKIN LESIONS | WASHINGTON UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| US-20170246299-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PRE-CANCEROUS SKIN LESIONS | WASHINGTON UNIVERSITY | 2017-08-31 | — | — | US | disclosed |
| US-20130006003-A1 | NEW SYNTHONES FOR PREPARATION OF 19-NOR VITAMIN D DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2013-01-03 | — | — | US | disclosed |
| US-20130006003-A1 | NEW SYNTHONES FOR PREPARATION OF 19-NOR VITAMIN D DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2013-01-03 | — | — | US | disclosed |
| US-20110137058-A1 | PREPARATION OF PARICALCITOL | FORMOSA LABORATORIES, INC. (TW) | 2011-06-09 | — | — | US | disclosed |
| US-20110137058-A1 | PREPARATION OF PARICALCITOL | FORMOSA LABORATORIES, INC. (TW) | 2011-06-09 | — | — | US | disclosed |
| WO-2011016739-A2 | NEW SYNTHONES FOR PREPARATION OF 19-NOR VITAMIN D DERIVATIVES | INSTYTUT FARMACEUTYCZNY (PL) | 2011-02-10 | — | — | WO | disclosed |
| US-20090275768-A1 | Preparation of Paricalcitol | FORMOSA LABORATORIES, INC. (TW) | 2009-11-05 | — | — | US | disclosed |
| US-20090275768-A1 | Preparation of Paricalcitol | FORMOSA LABORATORIES, INC. (TW) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110137058-A1 | PREPARATION OF PARICALCITOL | PTH1R, CYP24A1, CALCR | VDR 13/4885HDAC6 4472/4885HDAC3 4225/4885 |
| US-10905763-B2 | Compositions and methods for treatment of pre-cancerous skin lesions | TSLP, TP53, MKI67 | VDR 404/4885HDAC6 3558/4885HDAC3 4023/4885 |
| US-20230026855-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PRE-CANCEROUS SKIN LESIONS | TSLP, TP53, MKI67 | VDR 404/4885HDAC6 3558/4885HDAC3 4023/4885 |
| US-20170246299-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PRE-CANCEROUS SKIN LESIONS | TSLP, TP53, MKI67 | VDR 404/4885HDAC6 3558/4885HDAC3 4023/4885 |
| US-20130006003-A1 | NEW SYNTHONES FOR PREPARATION OF 19-NOR VITAMIN D DERIVATIVES | CYP24A1, CYP2R1, VDR | VDR 3/4885HDAC6 3588/4885HDAC3 1891/4885 |
| US-20090275768-A1 | Preparation of Paricalcitol | PTH1R, CYP24A1, CALCR | VDR 13/4885HDAC6 4472/4885HDAC3 4225/4885 |
| US-20210128732-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PRE-CANCEROUS SKIN LESIONS | TSLP, TP53, MKI67 | VDR 404/4885HDAC6 3558/4885HDAC3 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.